Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Tuesday, May 3, 2022

Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid‐19 pneumonia

alexandrossfakianakis shared this article with you from Inoreader

Abstract

We aimed to assess longitudinal changes in clinical indexes of Covid-19 patients with mild pulmonary infection during 5 days of remdesivir therapy, and determine the effect of age and gender on remdesivir adverse effects (AE). Patients' clinical data including inflammatory markers, liver and renal function tests, and heart rate (HR) were extracted from medical records. Linear mixed model (LMM) was used to analyze longitudinal changes in patients' clinical indexes. Gender and age were inserted in LMM as covariates to find their correlation with AE and clinical indexes. Of 84 patients, 35 patients met our criteria for the study. There were significant increases in mean levels of white blood cell (WBC) (p=0.005), alanine aminotransferase (ALT) (p=0.001), aspartate aminotransferase (AST) (p=0.001), blood urea nitrogen (BUN) (p=0.001), and creatinine (p=0.006) while mean levels of erythrocyte sedimentation rate (ESR) (p=0.005), C-reactive protein (CRP) (p=0.001), alkaline phosphatase (ALP) (p=0.001), and potassium (p=0.003) decreased, significantly. Estimated glomerular filtration rate (eGFR) (p=0.001) and HR (p=0.001) showed a notable decline over the course of treatment. LMM analysis showed that mean changes in WBC (β=0.94, p=0.029), creatinine (β=0.12, p=0.020), and HR (β=6.47, p=0.008) were greater in males than females. Also, age of patients had a significant effect on the mean changes of WBC (β= -0.02, p=0.023), sodium (β= -0.06, p=0.010), BUN (β=0.23, p=0.001), and HR (β= -0.29, p=0.001). Despite no renal and liver dysfunction, Covid-19 patients with mild pulmonary infection may develop some remdesivir AE, and attributed side effects might be affected by gender and age of patients.

This article is protected by copyright. All rights reserved.

View on the web

No comments:

Post a Comment